No abstract available.
Penicillamine*

For the purpose of further health control, D-penicillamine was orally administered to 8 persons who were employed in lead industry and suspected lead intoxication routine industrial health examination. The dose of D-penicillamine was 600 mg per day and was administered orally in every other 5 days. For the laboratory analyses 24 hours urine and 10 gm of whole blood were collected every day. The results were as follows ; 1. It was found that mean urinary lead excretion per day was 446.5 g/l and 394.98 g/l, respectively during the first 5-day and the second 5-day administration with D-penicillamine. 2. Mean lead excretion per day was 130.56 +/- 66.42 g/l after first 5-day administration and 159.28 +/- 104.44 g/l after second 5-day administration with D-penicillamine. 3. The level of urinary lead excretion after administration increased 3 to 4 times than that before administration with D-penicillamine. 4. Blood and urinary lead level investigate after 6 months were 44.4 +/- 10.2 g/100g and 72.7 +/- 29.7 g/l for the eight persons.
Humans ; Occupational Health ; Penicillamine*

In order to study the chelating action of d-penicillamine on lead and the possibility of its application to the provocation test for diagnosis of lead poisoning, urinary excretion of lead was measured from 24-hour urine samples before, during and after administration of d-penicillamine by oral route for 5 days on 18 lead workers. The results were as follows: 1. Oral d-penicillamine 600 mg/day raised the excretion of urinary lead by approximately 3 times as compared with initial urinary lead level. 2. Initial urinary lead level was the better indicator of urinary lead excretion in d-penicillamine administration than initial blood lead delta-ALA and hemoglobin level. 3. Oral d-penicillamine may be quite useful in provocation test for lead poisoning.
Diagnosis ; Lead Poisoning ; Penicillamine*

No abstract available.
Anemia, Aplastic* ; Penicillamine*

No abstract available.
Breast* ; Hepatolenticular Degeneration* ; Humans ; Penicillamine*

No abstract available.
Acantholysis* ; Captopril* ; Penicillamine* ; Rifampin* ; Skin*

For the purpose of the curative effects of oral D-penicillamine in lead Ip0soning,D-penicillamine was orally administered to 7 lead poisoned workers which were employed in glaze product industry dealing with the lead oxide (Pb3O4). The doses of D-penicillamine was 1, 200mg per day which was administered by oral 7days schedules, taking for 5 days and stopping for the following 2days, repeatedly during 3 months period-(All the poisoned workers started working again in that industry after I month treatment, and were treated by oral D-penicillamine for 2 months still being exposed to contaminated environment. In order to evaluate the curative effects of D-penicillamine, IOgm of whole blood and 24 hours urine were collected every 14 days during the curative period for laboratory analysis(hemoglobin, blood lead. urine c-aminolevulinic acid, urine coproporphyrin, and urine lead levels) with the observation of the clinical symptoms. The results were as follows; 1. Oral D-penicillamine effected good curative results as that hemoglobin, blood lead, urine caminolevulinic acid, and urine coproporphyrin levels were decreased belpiv the critical level within 1 month treatment. 2. After re-exposure, oral D-penicillamine effected to some extent as that urine lead level was decreased 'below the critical level after 3 months treatment with disappgarence of the clinical symptoms after 2 months treatment. However, the curative effects of orral D-penicillamine in the lead exposure state is questionable since increasement of blood lead' level and remarkable decreasement of urine lead level after 3 months treatment can be observed.
Appointments and Schedules ; Lead Poisoning* ; Penicillamine*

IgA nephropathy can occur rarely as a complication of D-penicillamine treatment, but it is exact pathogenesis remains unclear. If a patients has gross or microscopic hematuria during D-penicillamine treatment, D-penicillamine induced IgA nephropathy should be suspected as a cause of hematuria. In those cases, renal biopsy should be taken for diagnosis and proper management. We experienced a case of IgA nephropathy confirmed by renal biopsy in a 39-years-old female patient with scleroderma during D-penicillamine therapy and report this case with a review of literature.
Biopsy ; Diagnosis ; Female ; Glomerulonephritis, IGA* ; Hematuria ; Humans ; Immunoglobulin A* ; Penicillamine*

D-penicillamine, a chelating agent of copper, is the drug of choice for the treatment of Wilson's disease. Breast enlargement is a rare complication arising from its use, and we report a case of breast gigantism which developed after it had been used for ten months to treat this condition. Mammography demonstrated bilaterally enlarged dense breasts; ultrasonography, similarly, demonstrated enlargement, revealing the presence of a mass, shown at biopsy to be benign, in the left one.
Biopsy ; Breast* ; Copper ; Gigantism* ; Hepatolenticular Degeneration ; Mammography ; Penicillamine* ; Ultrasonography

OBJECTIVE: In order to compare the clinical effect and frequency of side effects between d-penicillamine and bucillamine, a chemical derivative of d-penicillamine, we conducted a randomized, controlled clinical trial. METHODS: 22 and 24 patients were allocated in each treatment arm, after stratification according to functional class, anatomical stage, and concomittant steroid use. We evaluated tender joint count, swollen joint count, tenderness score, duration of morning stiffness, and grip strength every 4 weeks. Westergren ESR, hemoglobin, leucocyte and platelet count were also checked every 4 weeks, and C-reactive protein(CRP)quantitation and rheumatoid factor(RF) titration were checked at baseline and 16 weeks. Study period spanned 16 weeks. RESULTS: At the end of the trial, both swollen joint count and tenderness score decreased significantly from baseline in both groups, whereas tender joint count decreased siginficantly in bucillamine-treated group only. Grip strength also improved significantly in bucillamine group. Duration of morning stiffness decreased in both groups. When we arbitrarily defined response as more than 30% decrease in both tender and swollen joint count from baseline, 27% of bucillamine group and 33% of d-penicillamine group responded. The response rate did not differ significantly between the 2 groups. ESR and RF decreased in both groups, whereas CRP decreased significantly only in bucillamine group. The frequency of side effects lasting more than 1 day and possibly related to drug was 14% and 37% in bucillamine and d-penicillamine group, respectively. The difference was statistically not significant. CONCLUSIONS: Bucillamine is as effective as d-penicillamine in the treatment of rheumatoid arthritis. The frequency of side effect tended to be lower.
Arm ; Arthritis, Rheumatoid* ; Hand Strength ; Humans ; Joints ; Penicillamine* ; Platelet Count